Opinion|Videos|July 8, 2024
Treatment Practices for Extended-Stage Small Cell Lung Cancer
Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.
Advertisement
Advertisement
Related to this article
Data presented at WCLC 2026 support the use of B7-H3–directed antibody-drug conjugates and brain MRI surveillance in small cell lung cancer.
The FDA reduced the recommended monitoring time for the first 2 doses of tarlatamab to 6 to 8 hours in extensive-stage small cell lung cancer.
Data from the phase 3 DeLLphi-305 trial also showed meaningful improvements in progression-free survival and responses with durvalumab/tarlatamab in SCLC.
Data from a real-world cohort showed that LEMS was diagnosed more frequently by neurologists than by oncologists.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
2
Fixed-Duration Combinations and MRD-Guided Therapy as Emerging Priorities in CLL
3
Japan Approves T-DXd Combo and Dato-DXd for First-Line Metastatic Breast Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5